E-LIB Suche - Ergebnisse für: Rinaldetti, Sébastien

1

High-Content Drug Discovery Targeting Molecular Bladder Can..:

Rinaldetti, Sébastien ; Zhou, Qiong ; Abbott, Joshua M....
International Journal of Molecular Sciences. 23 (2022) 18 - p. 10605 , 2022

Link: https://doi.org/10.3390/..

2

AST-487 Inhibits RET Kinase Driven TERT Expression in Bladd..:

Agarwal, Neeraj ; Zhou, Qiong ; Arya, Deepak...
International Journal of Molecular Sciences. 23 (2022) 18 - p. 10819 , 2022

Link: https://doi.org/10.3390/..

3

Isolating and targeting the real-time plasticity and malign..:

Esquer, Hector ; Zhou, Qiong ; Nemkov, Travis...
Oncogene. 40 (2021) 16 - p. 2884-2897 , 2021

Link: https://doi.org/10.1038/..

4

TRIM28 is a transcriptional activator of the mutant TERT pr..:

Agarwal, Neeraj ; Rinaldetti, Sebastien ; Cheikh, Bassem B....
Proceedings of the National Academy of Sciences. 118 (2021) 38 - p. , 2021

Link: https://doi.org/10.1073/..

5

Subtype specific expression and survival prediction of pivo..:

Rinaldetti, Sebastien ; Worst, Thomas Stefan ; Rempel, Eugen...
Scientific Reports. 10 (2020) 1 - p. , 2020

Link: https://doi.org/10.1038/..

6

Correction: High-risk additional chromosomal abnormalities ..:

Hehlmann, Rüdiger ; Voskanyan, Astghik ; Lauseker, Michael...
Leukemia. 34 (2020) 10 - p. 2823-2823 , 2020

Link: https://doi.org/10.1038/..

7

FOXA1 Gene Expression for Defining Molecular Subtypes of Mu..:

Sikic, Danijel ; Eckstein, Markus ; Wirtz, Ralph M....
Journal of Clinical Medicine. 9 (2020) 4 - p. 994 , 2020

Link: https://doi.org/10.3390/..

8

High-risk additional chromosomal abnormalities at low blast..:

Hehlmann, Rüdiger ; Voskanyan, Astghik ; Lauseker, Michael...
Leukemia. 34 (2020) 8 - p. 2074-2086 , 2020

Link: https://doi.org/10.1038/..

9

Diagnostic performance of the molecular BCR-ABL1 monitoring..:

Spiess, Birgit ; Rinaldetti, Sébastien ; Naumann, Nicole...
PLOS ONE. 14 (2019) 3 - p. e0214305 , 2019

Link: https://doi.org/10.1371/..

10

Drug Design Targeting T-Cell Factor-Driven Epithelial–Mesen..:

Abraham, Adedoyin D. ; Esquer, Hector ; Zhou, Qiong...
Journal of Medicinal Chemistry. 62 (2019) 22 - p. 10182-10203 , 2019

Link: https://doi.org/10.1021/..

11

FOXM1 overexpression is associated with adverse outcome and..:

Breyer, Johannes ; Wirtz, Ralph M. ; Erben, Philipp...
BJU International. 123 (2018) 1 - p. 187-196 , 2018

Link: https://doi.org/10.1111/..

12

The benefit of quality control charts (QCC) for routine qua..:

Spiess, Birgit ; Naumann, Nicole ; Galuschek, Norbert...
PLOS ONE. 13 (2018) 4 - p. e0196326 , 2018

Link: https://doi.org/10.1371/..

13

Subclassification, survival prediction and drug target anal..:

Rinaldetti, Sebastien ; Rempel, Eugen ; Worst, Thomas Stefan...
Oncotarget. 9 (2018) 40 - p. 25935-25945 , 2018

Link: https://doi.org/10.18632..

14

FOXM1 predicts disease progression in non-muscle invasive b..:

Rinaldetti, Sebastien ; Wirtz, Ralph ; Worst, Thomas Stefan...
Journal of Cancer Research and Clinical Oncology. 144 (2018) 9 - p. 1701-1709 , 2018

Link: https://doi.org/10.1007/..

15

Defining therapy goals for major molecular remission in chr..:

Saussele, Susanne ; Hehlmann, Rüdiger ; Fabarius, Alice...
Leukemia. 32 (2018) 5 - p. 1222-1228 , 2018

Link: https://doi.org/10.1038/..